Corticosteroids Versus NSAIDs on Intraocular Pressure and the Hypertensive Phase After Ahmed Glaucoma Valve Surgery

Yuen, Don; Buys, Yvonne M.; Jin, Ya-Ping; Alasbali, Tariq; Smith, Michael; Trope, Graham E.

doi:10.1097/ijg.0b013e3181efbec0

Cited by 35 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four trials evaluated an anti-vascular endothelial growth factor (VEGF) agent, with one trial using ranibizumab, Desai 2013, and three trials using bevacizumab (Arcieri 2015; Mahdy 2013; Rojo-Arnao 2011). Two trials evaluated a corticosteroid, with one trial comparing intravitreal triamcinolone versus none (Teixeira 2012), and another trial comparing topical dexamethasone versus topical ketorolac (Yuen 2011). Three trials investigated shunt augmentation, with one trial each comparing Ahmed implant with amniotic membrane, Yazdani 2016, biodegradable collagen matrix, Rho 2015, or pericardium, Hwang 2004, with Ahmed implant alone.…”

Section: Resultsmentioning

confidence: 99%

“…Ten trials measured mean logMAR visual acuity at varying time points of follow-up (ABC 2011; AVB 2011; Law 2016; Nassiri 2010; Pakravan 2007; TVT 2009; Wilson 2000; Wilson 2003; Yazdani 2016; Yuen 2011). We did not analyze dichotomous visual acuity data in this review due to variation in the outcome definitions used in each trial (e.g.…”

Section: Resultsmentioning

confidence: 99%

“…Two trials compared the duration of a recognizable postoperative hypertensive phase (Law 2016; Pakravan 2014), three trials compared the time to onset of the hypertensive phase (Law 2016; Nassiri 2010; Yuen 2011), and one trial compared the frequency of occurrence of a hypertensive phase (Rho 2015). …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…7,8 Prolonged use of topical steroids, however, was associated with higher incidence of HP than use of topical NSAIDs. 9 ) Use of sub-Tenon's triamcinolone acetonide injection during AGV surgery was shown to lower incidence of HP, but it did not improve long-term IOP control; additionally, it may be associated with more complications. 10 The fluocinolone acetonide intravitreal implant (Retisert; Bausch & Lomb, Bridgewater, NJ) enables sustained corticosteroid release over approximately 3 years into the vitreous cavity.…”

Section: Introductionmentioning

confidence: 99%

A retrospective study on the outcomes of Ahmed valve versus Ahmed valve combined with fluocinolone implant in uveitic glaucoma

et al. 2017

View full text Add to dashboard Cite

Purpose-To compare the intraocular pressure (IOP) outcomes of Ahmed glaucoma valve (AGV) surgery alone versus AGV with fluocinolone implant in uveitic glaucoma patients.Methods-We identified uveitic glaucoma patients with AGV surgery alone and AGV surgery combined with fluocinolone implant from the Massachusetts Eye and Ear Ocular Inflammation Database. Demographic information, visual acuity, and IOP were recorded at preoperative visits and 1, 6, and 12 months after surgery. Incidence of hypertensive phase, defined as an IOP of >21 mm Hg or use of additional treatment to lower IOP occurring any time between 7 days to 6 months postoperatively, was investigated. Multilevel mixed effects models were performed to compare the outcomes between groups.Results-Eighteen eyes of 13 uveitic glaucoma patients with 1-year follow-up data were included. There were 11 eyes of 9 patients (mean age, 56.5 years; 63.6% male) in the AGV group and 7 eyes of 4 patients (mean age, 61.3 years; 71.4% male) in the AGV + fluocinolone group. There was no significant difference in visual acuity change at 1 year after surgery between groups (P = 0.25), although visual acuity improvement was significant in the AGV group (P = 0.01). The hypertensive phase occurred in 91% of AGV patients and 43% of AGV + fluocinolone patients (P = 0.30), with onset of 8-40 days (mean, 18 days) after surgery. IOP and number of glaucoma medications decreased at the 1-year postoperative visits in both the AGV group (P < 0.0001, P < 0.0001) and the AGV + fluocinolone group (P = 0.001, P < 0.0001). Compared to the AGV group, the AGV + fluocinolone group used fewer glaucoma medications (0.28 vs 1.30 [P = 0.01]) and had better inflammation control (P = 0.02). The surgical complication rates were similar between groups.Conclusions-In uveitic glaucoma, AGV with fluocinolone achieves a similar, desired IOP control but with fewer glaucoma medications than AGV alone.

show abstract

“…In contrast, it produces more incision leak and conjunctival retraction problems. 68 Taking all this into account, it could be concluded that the use of topical NSAIDs (specifically kerotolac) could be useful in association with topical corticoids in the postoperative period of drainage implants.…”

Section: Profiles Of Drugs For Presurgery Suspensionmentioning

confidence: 99%